SiPhox Health vs Browser Use

Side-by-side comparison of AI visibility scores, market position, and capabilities

SiPhox Health leads in AI visibility (44 vs 30)
SiPhox Health logo

SiPhox Health

EmergingHealthcare

General

MIT-founded home blood testing company measuring 17 biomarkers via mail-in kits; Khosla-backed developing photonic chip for instant at-home results competing with Everlywell.

AI VisibilityBeta
Overall Score
C44
Category Rank
#1061 of 1158
AI Consensus
49%
Trend
up
Per Platform
ChatGPT
36
Perplexity
55
Gemini
50

About

SiPhox Health is a home blood testing company founded by MIT scientists that provides mail-in blood test kits measuring 17 key biomarkers — inflammation markers (CRP, homocysteine), cardiovascular health (LDL, HDL, triglycerides, ApoB), metabolic health (HbA1c, glucose, insulin), and hormone levels (testosterone, DHEA, cortisol) — with results delivered within days and integrated with an app for trend tracking and health guidance. Founded in 2020 by Diedrik Vermeulen and Michael Dubrovsky, SiPhox Health is backed by Khosla Ventures, Intel Capital, and Y Combinator.\n\nSiPhox's current product uses at-home finger-prick blood collection with mail-in testing — customers order a $95 kit, collect a small blood sample at home, and mail it to SiPhox's CLIA-certified lab for analysis. The $16/month membership provides regular testing on a quarterly or customizable schedule, enabling biomarker trend monitoring over time rather than single point-in-time snapshots. The underlying technology vision is a photonic chip (silicon photonics-based biosensor) that would enable instant at-home blood analysis without lab processing, with FDA clearance targeted for 2026.\n\nIn 2025, SiPhox Health competes in the home diagnostics and consumer health testing market with Everlywell (the leading at-home test kit brand), Function Health (comprehensive blood panel membership), InsideTracker, and traditional lab companies (LabCorp, Quest Diagnostics) for consumer blood testing. The longevity and proactive health monitoring movement has driven demand for comprehensive biomarker testing beyond what annual physicals provide. The potential photonic chip breakthrough would represent a significant technological leap — enabling truly point-of-care diagnostics without lab infrastructure. The 2025 strategy focuses on growing the biomarker panel subscription business, advancing the photonic chip development toward FDA clearance, and building clinical evidence for the personalized health intervention recommendations.

Full profile
Browser Use logo

Browser Use

EmergingDeveloper Tools

General

Browser Use is an open-source Python library that enables AI agents to control web browsers, making it easy for LLMs to interact with any website through a clean, model-agnostic API.

AI VisibilityBeta
Overall Score
D30
Category Rank
#365 of 1158
AI Consensus
66%
Trend
up
Per Platform
ChatGPT
35
Perplexity
28
Gemini
22

About

Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser automation frameworks like Playwright, providing a clean, model-agnostic interface that makes it straightforward for AI agents to navigate websites, fill forms, extract information, and complete multi-step web tasks without requiring developers to write custom browser control code.

Full profile

AI Visibility Head-to-Head

44
Overall Score
30
#1061
Category Rank
#365
49
AI Consensus
66
up
Trend
up
36
ChatGPT
35
55
Perplexity
28
50
Gemini
22
44
Claude
27
36
Grok
35

Key Details

Category
General
General
Tier
Emerging
Emerging
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.